Plot No-17/a, Phase-1, Ida, Patancheru, Dist, Medak, Telangana 502319
*The following content is generated by AI and is for reference only.
Overview
A fixed-dose combination tablet containing Vildagliptin 50mg and Metformin HCl 500mg. Vildagliptin (CAS: 204990-17-6) is a DPP-4 inhibitor, while Metformin (CAS: 1115-70-4) is a biguanide. The formulation utilizes direct compression or wet granulation to ensure stability and bioavailability.
Application
- Type 2 Diabetes Management: First-line therapy for glycemic control in adults.
- Combination Therapy: Used when monotherapy fails to maintain target HbA1c levels.
- Metabolic Syndrome: Adjunct treatment for insulin resistance profiles.
Precautions
- Contraindications: Severe renal impairment (eGFR < 30 mL/min) and metabolic acidosis.
- Safety: Monitor for lactic acidosis risk associated with Metformin.
- Storage: Store below 25°C in dry conditions to prevent hydrolysis.